# US 2013/0280340 A1 · Compositions and methods of using lamellar bodies for modifying linear biological macromolecules > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0280340 A1 - Document ID: US20130280340A1 - Status: Published application - Kind: A1 - Application number: 13/915,779 - Filed: 2013-06-12 - Published: 2013-10-24 - Earliest claimed: 2003-09-25 - Assignees: Lamellar Biomedical Limited - Inventors: James Dobbie - Web page: https://patentgrep.com/patent/US20130280340A1 ## CPC - A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) - A61K 9/0043: {Nose} - A61K 9/0046: {Ear} - A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant - A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol - A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols - A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin - A61K 31/688: both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins - A61P 11/00: Drugs for disorders of the respiratory system - A61P 27/00: Drugs for disorders of the senses - A61P 27/16: Otologicals - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Compositions comprising therapeutically effective amounts of lamellar bodies to restore lubricity and non-stick properties to mucous surfaces for conditions characterised by dry adherent surfaces, particularly those surfaces close to the body openings and conditions of the eye. ## Claims ### Claim 1 A method of treating areas affected by mucositis to restore lubricity and non-stick properties to dry adherent surfaces or solubilised crusting and to prevent the formation of synechiae wherein the method comprises applying a composition including lamellar bodies to the mucous surfaces in a subject in need thereof. ### Claim 2 (depends on 1) The method of claim 1 wherein the mucositis is characterised by dryness of mucous surfaces. ### Claim 3 (depends on 2) The method of claim 2 wherein the dryness of mucous surfaces is of the buccal cavity, oropharynx or larynx. ### Claim 4 (depends on 1) The method of claim 1 wherein the lamellar bodies are provided in a variety of forms including aerosol spray with or without ultrasonification, a suspension or gel. ### Claim 5 (depends on 1) The method of the claim 1 wherein the mucositis is caused by radiation, chemotherapeutic agents, drugs, auto-immunity, allergies and infections. ### Claim 6 (depends on 1) The method of claim 1 wherein the characteristic feature of the mucositis is dryness of the surfaces which become covered with sticky exudates consisting of viscous mucus, viscous DNA and actin from dead cells and bacteria. ### Claim 7 (depends on 1) The method of claim 1 wherein the mucositis is caused by one of Stevens-Johnson syndrome, Pemphigus, Behcet's disease, systemic lupus erythematosis or other bullous disorders. ### Claim 8 (depends on 1) The method of claim 1 wherein the area affected is the external surfaces of the eye. ### Claim 9 (depends on 1) The method of claim 1 wherein the area affected is the mucous membrane of the eyelids and the conjuctivae. ### Claim 10 (depends on 8) The method of claim 8 wherein the external surface of the eye is dry and/or covered by thickened viscous secretion or exudates. ### Claim 11 (depends on 10) The method of claim 10 wherein the exudates form crusts whose abrasive effect further excoriates and traumatises the surface. ### Claim 12 (depends on 8) The method of claim 8 wherein the dryness of the eye is keratoconjunctivitis sicca. ### Claim 13 (depends on 8) The method of claim 8 wherein the dryness of the eye is blepharitis and conjunctivitis. ### Claim 14 (depends on 8) The method of claim 8 wherein the dryness of the eye is caused by an autoimmune disorder, or rheumatoid or Sojgren's syndrome. ### Claim 15 (depends on 8) The method of claim 8 wherein the lamellar bodies are applied in the form of gel, matrices or slow release devices or excipients. ### Claim 16 (depends on 1) The method of claim 1 wherein the composition comprises lamellar bodies comprising about 44-70% phosphatidylcholine about 15-23% sphingomyelin about 6-10% phosphatidyl ethanolamine about 2-6% phosphatidyl serine about 2-4% phosphatidyl inositol and about 4-12% cholesterol by weight. ### Claim 17 (depends on 16) The method of claim 16 wherein said composition further comprises about 0-3% by weight of lysophosphatidyl choline. ### Claim 18 (depends on 16) The method of claim 16 wherein said lamellar bodies comprise about 54% phosphatidylcholine, about 19% sphingomyelin about 8% phosphatidyl ethanolamine about 4% phosphatidyl serine about 3% phosphatidyl inositol and about 10% cholesterol by weight. ### Claim 19 (depends on 16) The method of claim 16 wherein said composition comprises about 2% by weight of lysophosphatidyl choline.